Mantle cell lymphoma stage II

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
1 Unique sponsors
2 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
N Neurology/Psychiatry (ATC N) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 1 substance
BTK inhibitor 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Klinikum der Universitaet Muenchen AöR Academic
    IMP not specified
    2024-511235-10-00 12 countries 2016 n=832
    Ended

Phase II

1 trial
  • Klinikum der Universitaet Muenchen AöR Academic
    BREXUCABTAGENE AUTOLEUCEL; IBRUTINIB
    2022-502405-15-01 5 countries 2024 n=150 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Klinikum der Universitaet Muenchen AöR Academic 2 Phase II, Phase III 1
New trials by year
2024
1
← All indication landscapes